Know Labs Raises $3.445 Million in Public Offering

Know Labs, Inc. (NYSE American: KNW), a prominent developer of non-invasive medical diagnostic technology, has announced the pricing of a public offering of 13,250,000 units at $0.26 per unit. Each unit comprises one share of common stock and one warrant to purchase an additional share at the same price. The company has also provided underwriters with a 30-day option to acquire up to 1,987,500 additional shares and warrants at specified prices, subject to underwriting discounts. The offering is backed by a registration statement filed with the Securities and Exchange Commission (SEC), which was declared effective on August 7, 2024. Interested investors can access the final prospectus through the SEC’s website or request it from The Benchmark Company, LLC, or Boustead Securities, LLC. The company emphasizes that this announcement does not constitute an offer to sell or solicit offers to buy the securities in jurisdictions where such actions would be illegal. The initial application of Know Labs' technology will be in a non-invasive glucose monitoring product. The release includes forward-looking statements regarding the company's future performance, financing plans, and growth strategies, which are subject to various risks and uncertainties. Investors are advised to review the company's filings with the SEC for a comprehensive understanding of these risks. Know Labs, Inc. does not undertake any obligation to update forward-looking statements following the date of this announcement, and potential investors are encouraged to consider the inherent uncertainties involved.